**Education and Professional Experience:** Graduated from the Clinical Medicine program of Sun Yat-sen University of Medical Sciences in 1994. Since graduation, has been working in the Department of Gastroenterology at the First Affiliated Hospital of Sun Yat-sen University. From 2005 to 2006, pursued advanced studies at Prince of Wales Hospital in Hong Kong. Obtained a Doctorate in Internal Medicine from Sun Yat-sen University in 2007. **Social Appointments:** 1. Member, Psychological Collaboration Group, Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association 2. Member, Capsule Endoscopy Collaboration Group, Chinese Society of Digestive Endoscopy, Chinese Medical Association 3. Deputy Head, Inflammatory Bowel Disease Group, Guangdong Medical Association Gastroenterology Branch 4. Deputy Head, Small Intestine Endoscopy Professional Group, Digestive Endoscopy Physician Branch, Guangdong Medical Doctor Association 5. Member, Gastroenterology Physician Branch, Guangdong Medical Doctor Association 6. Deputy Head, Youth Academic Group, Chinese Journal of Inflammatory Bowel Diseases **Publications:** 1. Zhang SH, Chen BL (co-first author), Wang BM, Chen H, Li Y, Cao Q, Chen MH. Effect of induction therapy with Olamkicept vs placebo on clinical response in patient with active ulcerative colitis. JAMA. 2023;329(9):1-10 2. Chen BL, Zhong J, Li XL, Pan F, Ding TJ, Zhang Y, Chen H, Liu F, Zhang ZY, Zhang L, Rafal Drozda, Oleksandr Oliinyk, Aik Han Goh, Chen X, Sun X; David T Rubin, William J Sandborn, Chen MH; Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study, Gastroenterology, 2022 3. Zhuang XJ, Chen BL (co-first author), Huang SS, Han J, Zhou GS, Xu S, Chen MH, Zeng ZR, Zhang SH. Hypermethylation of miR-145 promoter-mediated SOX9-CLDN8 pathway regulates intestinal mucosal barrier in Crohn's disease, EBioMedicine, 2022, 76 4. Chen BL, Gao X, Zhong J, Ren JL, Zhu X, Liu ZJ, Wu KC, Jasmina Kalabic, Yu ZQ, Bidan Huang, Nisha Kwatra, Thao Doan, Anne M. Robinson, Chen HM. Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial, Therap Adv Gastroenterol, 2020, 13. 5. Feng T, Chen BL (co-first author), Bella Ungar et al. Association of Infliximab Levels With Mucosal Healing Is Time-Dependent in Crohn’s Disease: Higher Drug Exposure Is Required Postinduction Than During Maintenance Treatment. Inflamm Bowel Dis 2019;25(11):1813-1821 6. Feng T, Chen B (co-first author), Li L, Huang S, Ben-Horin S, Qiu Y, Feng R, Li M, Mao R, He Y, Zeng Z, Zhang S, Chen M. Serum Interleukin 9 Levels Predict Disease Severity and the Clinical Efficacy of Infliximab in Patients with Crohn's Disease. Inflamm Bowel Dis, 2017, 23(10): 1817-1824. 7. Qiu Y, Chen BL (co-first author), Mao R, Zhang SH, He Y, Zeng ZR, Ben-Horin S, Chen MH. Systematic Review with Meta-Analysis: Loss of Response and Requirement of anti-TNFalpha Dose Intensification in Crohn's Disease. J Gastroenterol, 2017, 52(5): 535-554. **Monographs:** Crohn's Disease: Basic Research and Clinical Practice Ulcerative Colitis: Basic Research and Clinical Practice